ANGIODROID has designed and developed a medical product for angiography that avoids the use of iodine as a contrast agent, using, instead, an injection of CO2 gas. This innovation allows the carrying out of the diagnostic test on patients with renal insufficiency. The product makes the injection absolutely safe, without the risk of emboli or excessive pressure associated with the manual administration of CO2. The company also provides specific single-use kits to perform new types of angiographies.
Date of investment September, 2013
Offices San Lazzaro di Savena, Italy
Sebastiano Zannoli
Founder & CEO
